8-Acetonyldihydronitidine
8‑Acetonyldihydronitidine is a naturally occurring benzophenanthridine alkaloid with antibacterial, antifungal, and anti-proliferative activities against colorectal cancer cells. 8‑Acetonyldihydronitidine inhibits Staphylococcus aureus and exerts a potent antifungal effect against Cladosporium cladosporioides. 8‑Acetonyldihydronitidine activates the p53 signaling pathway, upregulates the expression of target genes including p21, BAX, and FAS, downregulates cyclin A and cyclin B, and induces cell cycle arrest and apoptosis, thereby suppressing the proliferation of colorectal cancer cells. 8‑Acetonyldihydronitidine is used in research related to colorectal cancer, fungal infections, and bacterial infections.
For research use only. We do not sell to patients.
- CAS No.: 80330-39-8
- Formula: C24H23NO5
- Molecular Weight:405.45
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
CDK1/cyclin A |
CDK2(C118L/A144C-Cyclin B) |
Caspase 3 |
Bax |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
5.38 μM
|
Antiproliferative activity against human HCT116 colorectal cancer cells assessed as reduction in cell viability incubated for 48 h by MTT assay.
Antiproliferative activity against human HCT116 colorectal cancer cells assessed as reduction in cell viability incubated for 48 h by MTT assay.
|
j.ejphar.2019.03.042 |
| LoVo | IC50 |
5.81 μM
|
Antiproliferative activity against human LOVO colorectal cancer cells assessed as reduction in cell viability incubated for 48 h by MTT assay.
Antiproliferative activity against human LOVO colorectal cancer cells assessed as reduction in cell viability incubated for 48 h by MTT assay.
|
j.ejphar.2019.03.042 |
| HCT-15 | IC50 |
12.91 μM
|
Antiproliferative activity against human HCT15 colorectal cancer cells assessed as reduction in cell viability incubated for 48 h by MTT assay.
Antiproliferative activity against human HCT15 colorectal cancer cells assessed as reduction in cell viability incubated for 48 h by MTT assay.
|
j.ejphar.2019.03.042 |
| SW480 | IC50 |
9.33 μM
|
Antiproliferative activity against human SW480 colorectal cancer cells assessed as reduction in cell viability incubated for 48 h by MTT assay.
Antiproliferative activity against human SW480 colorectal cancer cells assessed as reduction in cell viability incubated for 48 h by MTT assay.
|
j.ejphar.2019.03.042 |
In Vitro
8-Acetonyldihydronitidine (8-AHN) (0-80 µM; 48 h) effectively inhibits the proliferation of HCT116, LOVO, HCT15, and SW480 human colorectal cancer cells, with the lowest IC50 of 5.38 µM observed in HCT116 cells[1].
8-Acetonyl dihydronitidine (5 µM; 0-48 h) induces G2/M phase cell cycle arrest in synchronized HCT116 human colorectal cancer cells in a time-dependent manner[1].
8-Acetonyl dihydronitidine (0-8 µM; 24 h) downregulates cyclin A and cyclin B at both the protein and mRNA levels in HCT116 and LOVO human colorectal cancer cells[1].
8-Acetonyl dihydronitidine (2-10 µM; 0-48 h) induces apoptosis in HCT116 human colorectal cancer cells in a time- and dose-dependent manner, and the level of cleaved caspase-3 increases after treatment at a concentration of 8 µM for 24 h[1].
8-Acetonyldihydronitidine enhances the expression and transcriptional activity of p53 in HCT116 human colorectal cancer cells, and upregulates the p53 target genes p21, BAX and FAS after 24 h of treatment[1].
8-Acetonyl dihydronitidine (compound 1) inhibits the growth of Staphylococcus aureus, with an MIC of 1.56 μg/mL and an MBC of 25 μg/mL[2].
8-Acetonydihydronitidine exhibits potent antifungal activity against Cladosporium cladosporioides (100 mm2 inhibition zone at 2 mg), and inhibits more than 90% of conidial germination of Colletotrichum gloeosporioides after 6 h of treatment at a concentration of 200 μg/mL[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCT116, HCT15, LOVO, SW480 human colorectal cancer cell lines
-
Concentration:0, 0.25, 0.5, 1, 2.5, 5, 10, 20, 40, 80 µM
-
Incubation Time:48 h
-
Result:Suppressed proliferation in all four cell lines in a concentration-dependent manner.
Exhibited IC50 values of 5.38 µM for HCT116 cells, 5.81 µM for LOVO cells, 12.91 µM for HCT15 cells, and 9.33 µM for SW480 cells.
Showed the highest sensitivity in HCT116 and LOVO cells.
-
Cell Line:synchronized HCT116 human colorectal cancer cells
-
Concentration:5 µM
-
Incubation Time:0 h, 24 h, 48 h
-
Result:Caused a time-dependent increase in the proportion of cells in the G2/M phase.
Increased G2/M phase proportion from 29.2% at 0 h to 53.1% at 24 h and 57.9% at 48 h.
-
Cell Line:HCT116 and LOVO human colorectal cancer cells
-
Concentration:0, 2, 4, 6, 8, 10 µM
-
Incubation Time:24 h
-
Result:Decreased the protein levels of cyclin A and cyclin B in both HCT116 and LOVO cells in a dose-dependent manner.
Significantly increased the protein level of cleaved caspase-3 at the 8 µM dose along with other cleaved apoptotic markers in a dose-dependent manner after 24 h.
Significantly increased protein level of p53 transcriptional targets p21, BAX, and FAS upon treatment.
-
Cell Line:HCT116 and LOVO human colorectal cancer cells
-
Concentration:0, 4, 8 µM
-
Incubation Time:24 h
-
Result:Reduced mRNA expression of both cyclin B and cyclin A within 24 h of treatment in a dose-dependent manner.
Significantly increased mRNA level of p53 transcriptional targets p21, BAX, and FAS upon treatment.
-
Cell Line:HCT116 human colorectal cancer cells
-
Concentration:5 µM
-
Incubation Time:0 h, 24 h, 48 h
-
Result:Increased the combined percentage of early and late apoptotic cells from 2.35% at 0 h to 21.49% at 24 h and 31.57% at 48 h at 5 µM.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (male; 5 weeks old; 15-18 g; HCT116 human colorectal cancer cell subcutaneous xenograft)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every other day; 2 weeks
-
Result:Significantly inhibited the growth of HCT116 xenograft tumors.
Reduced average excised tumor weight to 300 mg.
Decreased tumor volume relative to the vehicle control group.
Did not cause significant body weight loss in treated animals.
Increased expression of BAX and p53 in tumor sections.
Decreased expression of cyclin B and PCNA in tumor sections.
Showed no major organ-related toxicities in lung and liver.
Chemical Information
-
CAS No. 80330-39-8
-
Molecular Weight 405.45
-
Formula C24H23NO5
-
SMILES
O=C(C)CC1C2=CC(OC)=C(OC)C=C2C=3C=CC4=CC=5OCOC5C=C4C3N1C
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)